Retatrutide (LY3437943) is a triple receptor agonist that simultaneously activates glucagon-like peptide-1 receptors (GLP-1R), glucose-dependent insulinotropic polypeptide receptors (GIPR), and glucagon receptors (GCGR). This three-way engagement is the defining structural difference from earlier compounds in the class: semaglutide targets GLP-1R only; tirzepatide adds GIPR to GLP-1R but leaves glucagon signalling untouched. The glucagon arm is what makes retatrutide novel — glucagon receptor activation is understood in research models to contribute to energy expenditure in ways that GLP-1 agonism alone does not, which is why the Phase 2 data drew such immediate attention from metabolic researchers worldwide, including an increasingly active research community across Dubai, Abu Dhabi, and the broader UAE.
The landmark Jastreboff et al. 2023 paper published in the New England Journal of Medicine reported the Phase 2 randomised controlled trial of retatrutide in participants with obesity. At 24 weeks, the highest-exposure research cohorts showed mean body-weight reductions exceeding 17%. The 48-week extension of that same cohort reached approximately 24% mean reduction in the per-protocol population. These figures attracted global headlines because they numerically outpaced any previously published GLP-1 or dual-agonist dataset at equivalent observation windows. UAE researchers who track the metabolic peptide literature have been citing this paper since its publication, and it remains the foundational document for any retatrutide research programme entering Month 1.
The Eli Lilly TRIUMPH programme is the ongoing Phase 3 clinical trial suite for retatrutide, designed to move the compound toward regulatory consideration. TRIUMPH trials span multiple populations including adults with obesity only, adults with type 2 diabetes, and cardiovascular risk subgroups. Phase 3 extends observation windows beyond Phase 2, expands sample sizes substantially, and measures harder clinical endpoints — including cardiovascular events, long-term safety, and insulin sensitivity markers — that Phase 2 was not powered to evaluate definitively. For UAE researchers designing their own exploratory protocols, TRIUMPH readouts represent the next authoritative data signal, and REVIVE LAB UAE will publish summaries on this blog as those results enter the public domain.
REVIVE LAB UAE carries retatrutide in two formats: 5mg lyophilised vials and 10mg lyophilised vials. Both are maintained in cold storage at our Dubai facility and are available for same-day dispatch. Live stock status is updated in real time at /buy-retatrutide-uae/. For UAE researchers who have previously ordered from international suppliers and experienced 2–3 week courier delays through DXB customs, in-country stock is a material operational advantage — particularly for protocols with weekly administration schedules where a supply gap disrupts continuity.
The Jastreboff et al. 2023 NEJM Phase 2 trial used an escalating dose structure across its research cohorts, examining weekly subcutaneous administration at titration levels including 2mg, 4mg, and 8mg. These figures are reproduced here directly from the published peer-reviewed trial record and cited for informational reference only. REVIVE LAB UAE does not provide dosing guidance, administration protocols, or titration advice for any purpose. Researchers designing retatrutide protocols should consult the primary literature and their institutional research ethics board.
All retatrutide vials from REVIVE LAB UAE are lyophilised (freeze-dried) powder. This format is the correct choice for the UAE research context for one straightforward reason: ambient temperatures in Dubai, Abu Dhabi, and Sharjah regularly exceed 40°C in summer. Pre-mixed peptide solutions degrade within hours when exposed to heat — a serious risk during the final-mile delivery leg, even with insulated packaging. Lyophilised vials are significantly more stable during transit and hold their integrity much longer in storage, providing researchers with the flexibility to reconstitute only the volume required for each research application.
| Vial Format | Available Sizes | Recommended Storage | Post-Reconstitution Stability |
|---|---|---|---|
| Lyophilised powder | 5mg | −20°C long-term; 2–8°C up to 4 weeks | Up to 28 days at 4°C |
| Lyophilised powder | 10mg | −20°C long-term; 2–8°C up to 4 weeks | Up to 28 days at 4°C |
Standard laboratory practice for lyophilised peptide reconstitution uses sterile bacteriostatic water (preserved with 0.9% benzyl alcohol) or sterile water for injection. Bacteriostatic water is the preferred option for multi-draw research vials because the benzyl alcohol acts as a preservative, allowing the reconstituted solution to remain microbially safe for repeated access over the research period. Plain sterile water for injection is appropriate for single-use applications where the entire volume will be used immediately. REVIVE LAB UAE does not supply reconstitution solvents, but they are available from licensed laboratory supply distributors operating across Dubai, Abu Dhabi, and Sharjah.
Lyophilised retatrutide vials should be stored at −20°C for long-term integrity. For active research periods where the vial will be accessed regularly within a month, storage at 2–8°C is appropriate. Once reconstituted, the research solution should be refrigerated at 4°C and used within 28 days. The UAE climate creates a genuine cold-chain challenge that researchers in more temperate climates do not face: ambient outdoor temperatures in July across Dubai, Sharjah, and Abu Dhabi regularly hit 42–45°C. REVIVE LAB UAE ships all orders in insulated, temperature-controlled packaging regardless of delivery zone — including longer runs to outer Palm Jumeirah fronds and Abu Dhabi deliveries on the Sheikh Zayed Road corridor.
Repeated freeze-thaw cycles are documented to degrade peptide purity and structural integrity in standard laboratory research literature. Best practice for lyophilised peptides is to reconstitute only the volume required for the immediate application and aliquot remaining volume into single-use micro-portions at the point of reconstitution. Freezing the reconstituted solution in individual aliquots, then thawing only one aliquot per application session, is the standard mitigation strategy used by professional research laboratories and eliminates repeated freeze-thaw exposure to the bulk reconstituted volume.
REVIVE LAB UAE sources retatrutide meeting a minimum 98% HPLC purity standard. Certificate of Analysis documentation is available per batch and provided on request for all institutional orders. For UAE-based research institutions — whether operating in Business Bay, in Abu Dhabi's healthcare district, or in Sharjah university research campuses — CoA-backed documentation from an in-country stock holder simplifies both institutional procurement records and compliance requirements compared to importing from overseas suppliers with no local presence.
Yes. REVIVE LAB UAE holds physical stock in Dubai and dispatches same-day for research orders placed before the daily cut-off. Delivery coverage includes all central Dubai zones: DIFC, Downtown Dubai, Business Bay, Dubai Marina, JBR, Jumeirah, Al Quoz, and Palm Jumeirah. The practical significance of same-day UAE stock availability versus ordering from international suppliers is not trivial: international DHL shipments for research peptides currently face 10–21 day delivery windows from Europe or North America to DXB, with the added risk of customs examination, temperature exposure in the DXB cargo shed, and potential clearance delays. For researchers on a weekly protocol schedule, a supply interruption of even 7 days is operationally disruptive.
REVIVE LAB UAE ships to all seven emirates. Abu Dhabi and Sharjah orders typically arrive next-day. Al Ain, Fujairah, and Ras Al Khaimah are served on a 1–2 day schedule. All shipments use temperature-controlled packaging regardless of destination. The Abu Dhabi–Dubai corridor in July places uninsulated packages under significant thermal stress even during a 90-minute transit, which is why REVIVE LAB UAE does not compromise on cold-chain packaging for any delivery zone in the UAE.
All REVIVE LAB UAE orders ship in plain, unmarked outer packaging. There are no product names, brand logos, peptide references, or content indicators on the exterior of the package. Inner packaging is laboratory-standard cold-chain material. UAE research clients who receive deliveries at commercial premises in Business Bay, at residential addresses in Dubai Marina, or at clinical and academic facilities in Abu Dhabi can accept deliveries without unnecessary attention to the contents. This discreet packaging approach is standard and non-negotiable for all orders.
REVIVE LAB UAE accepts: cash on delivery (COD) across the UAE, bank transfer, and Binance Pay (USDT TRC20) with a 5% pre-pay discount applied automatically. COD remains the most-used option for UAE-based research clients who prefer to verify documentation and packaging integrity at the door before payment. The Binance Pay option is used frequently by research institutions and individual researchers who process procurement in stablecoins, and by clients outside Dubai where COD logistics are less convenient. Order via WhatsApp to confirm your preferred payment method at checkout.
No mandatory minimum. A researcher beginning a new protocol with a single 5mg retatrutide vial can place an order directly through the product page. REVIVE LAB UAE operates as a B2B research supplier and serves the full range from individual researchers at DXB-adjacent labs to institutional research departments ordering in multi-vial batches. For orders of 10 or more vials, contact the REVIVE LAB UAE team via WhatsApp for volume pricing, scheduled delivery arrangements, and dedicated batch documentation.
| Delivery Zone | Speed | Cold-Chain Packaging | COD Available |
|---|---|---|---|
| Dubai: Marina, JBR, Business Bay, DIFC, Downtown, Al Quoz | Same-day | Yes | Yes |
| Dubai: Palm Jumeirah, Jumeirah Islands, Dubai Hills | Same-day | Yes | Yes |
| Abu Dhabi / Sharjah | Next-day | Yes | Yes |
| Al Ain / Fujairah / Ras Al Khaimah / Ajman / UAQ | 1–2 days | Yes | Yes |
In the structure used by the Jastreboff et al. 2023 NEJM Phase 2 trial, the early weeks of a retatrutide research protocol served as an onboarding and tolerance-characterisation phase. The escalating dose structure used in that trial was specifically designed to document early-phase response patterns in the research cohort before advancing to higher exposure tiers. In practice, Month 1 is where researchers establish baseline measurements, document initial response patterns across the endpoint set they are tracking, and calibrate the escalation cadence that will govern the rest of the protocol. Month 1 data typically looks different from Month 3 or Month 6 data in terms of which metabolic parameters shift most prominently and how quickly.
UAE researchers designing retatrutide protocols typically establish baselines for the parameters most likely to be informative under triple-agonist exposure. These commonly include body composition proxies, fasting glucose, insulin resistance markers, lipid panels (LDL, HDL, triglycerides), hepatic enzyme levels, and relevant cardiovascular markers. The TRIUMPH Phase 3 primary and secondary endpoint structure — which is in the public trial registry — provides a useful reference framework for what the research literature currently considers the most signal-rich domains for retatrutide investigation, even for researchers working in non-clinical exploratory contexts.
The GLP-1 arm of retatrutide's mechanism has the most immediate research-observable effect — gastric transit modulation is a well-characterised early signal across the GLP-1 compound class. The GIPR arm contributes to glucose-dependent insulin regulation, an effect that is also observable relatively early in a research timeline. The glucagon receptor arm — the novel component — is theorised by researchers to contribute incrementally to energy expenditure over longer observation windows. Month 1 research data therefore tends to be dominated by GLP-1-mediated signal patterns, with the glucagon arm's contribution becoming progressively more evident as the protocol extends into Month 2 and beyond.
Some UAE research programmes explore retatrutide alongside peptides targeting complementary biological pathways — for example, peptides with documented roles in lean tissue biology or metabolic signalling. There is no published peer-reviewed combination protocol specifically validated for retatrutide alongside other compounds in the available literature, and REVIVE LAB UAE does not recommend or endorse any multi-peptide combination design. Researchers designing such exploratory protocols should treat them as hypothesis-generating, document methodology rigorously, and obtain appropriate institutional ethics clearance before proceeding.
The Jastreboff et al. 2023 NEJM Phase 2 trial was a global multi-site study; MENA-specific subgroup data from that trial has not been separately published. TRIUMPH Phase 3 enrollment includes Middle East sites, and MENA subgroup analyses may emerge in future publications. This is a genuine research gap that UAE-based investigators are well-positioned to contribute to. The UAE's distinctive metabolic research context — elevated population rates of metabolic syndrome components, specific dietary patterns, largely indoor-sedentary occupational structures, and extreme ambient climate conditions — creates a research environment that differs meaningfully from the Western populations that dominate the existing trial literature.
Semaglutide is a selective GLP-1R mono-agonist. Retatrutide adds GIPR and GCGR activity on top of GLP-1R agonism, making direct protocol comparison non-trivial — the receptor profile differences mean the measured endpoint set and observed response patterns are structurally different, not just quantitatively larger. Researchers who have designed semaglutide-focused metabolic protocols will need to extend their endpoint tracking to accommodate the GIP and glucagon signalling components that retatrutide uniquely engages. Phase 2 data suggests the triple-agonist architecture produces larger magnitude shifts in body composition endpoints at equivalent timepoints than the semaglutide Phase 3 historical record, though direct head-to-head randomised trials are not yet in the published literature.
Tirzepatide is a dual GIP/GLP-1 agonist — it matches two of retatrutide's three receptor targets but lacks glucagon receptor activity. The glucagon arm is the architectural differentiator. From a practical lab-operations standpoint, UAE researchers who have previously worked with tirzepatide will find retatrutide protocols analogous in terms of reconstitution procedure, storage requirements, and administration route. The transition from a tirzepatide research programme to a retatrutide programme is operationally straightforward — the main adaptation required is in endpoint design, to ensure the glucagon-driven signal domains are included in the tracking framework.
REVIVE LAB UAE stocks both GHK-Cu — a copper tripeptide with a well-documented research record in tissue repair and collagen synthesis models (Pickart et al. 2018, Cosmetics) — and Tesamorelin, one of our bestselling UAE peptides. Some UAE research teams design exploratory protocols examining retatrutide alongside growth-hormone-axis or tissue-biology peptides. These are hypothesis-generating designs with no specific published peer-reviewed validation of combined protocols. Researchers exploring multi-peptide protocols should treat each compound's contribution independently in their documentation and consult institutional ethics guidance before proceeding.
Retatrutide is not approved by the UAE Ministry of Health and Prevention, the FDA, the EMA, or any major regulatory authority as a licensed therapeutic. It remains an investigational compound in Phase 3 clinical development globally. REVIVE LAB UAE supplies retatrutide as a research-use-only material for laboratory and non-clinical scientific research. All purchasers confirm at point of sale that the material is acquired for research purposes only and not for human or veterinary administration. UAE researchers should review and comply with their institution's research ethics protocols and any applicable UAE regulatory framework governing the acquisition and use of investigational research compounds.
Professional UAE research environments — including labs in Business Bay, Abu Dhabi's SEHA-affiliated facilities, DXB-adjacent pharmaceutical research operations, and university research campuses in Sharjah — typically process peptide procurement through their institutional purchasing systems. REVIVE LAB UAE provides formal tax invoices, batch numbers, and Certificate of Analysis documentation with every order to support institutional procurement records and internal research compliance requirements. For recurring institutional supply needs, the REVIVE LAB UAE team can establish standing order arrangements with scheduled delivery and consolidated documentation packages. Contact us via WhatsApp to discuss institutional account setup.
REVIVE LAB UAE (revivelab.ae) maintains in-country stock of retatrutide 5mg and 10mg lyophilised research vials and dispatches same-day across Dubai — Marina, JBR, Business Bay, DIFC, Downtown, and Palm Jumeirah. Next-day delivery is available for Abu Dhabi and Sharjah. All orders ship in discreet, temperature-controlled packaging with COD available.
REVIVE LAB UAE stocks retatrutide in 5mg and 10mg lyophilised vials, supplied with Certificate of Analysis documentation for each batch. These are research-use-only materials, not intended for human or veterinary administration. Check live stock availability at /buy-retatrutide-uae/.
The Jastreboff et al. 2023 NEJM Phase 2 trial examined weekly subcutaneous administration at titration levels including 2mg, 4mg, and 8mg across its research cohorts. These numbers are drawn directly from the published peer-reviewed trial and are reproduced here for reference only. REVIVE LAB UAE does not provide dosing guidance, administration protocols, or titration advice for any purpose whatsoever.